Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company developing
potentially life-changing technologies for patients with cancer and diabetes,
today announced the appointment of Shannon Inman as Vice President of Global
Clinical Operations. According to the update, Inman will lead in defining
clinical developmental strategies, clinical protocol design, study conduct, and
managing risk assessment in this new position. These clinical trials include
those with Genprex’s lead drug candidate, Oncoprex(TM), for non-small cell lung
cancer (“NSCLC”), which recently received Fast Track Designation for its combination
with osimertinib, AstraZeneca’s first-line targeted EGFR TKI drug Tagrisso(R).
“Genprex continues to strengthen its leadership team with the appointment of an
accomplished executive to drive the launch of key clinical trials,” Genprex
Chairman and CEO Rodney Varner said in the news release. “Ms. Inman brings a
wealth of experience in the pharmaceutical industry, having successfully
directed a number of development programs in both large and small biotechnology
companies and top tier academic institutions. She will be instrumental in
continuing to build the long-term value of our gene therapies. With the
addition of our second investigational gene therapy asset addressing the unmet
medical need of people suffering from diabetes, I’m excited about building the
necessary infrastructure to facilitate our growth.”
To view the full press release, visit http://ibn.fm/oCfHZ
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with cancer and
diabetes. Genprex’s technologies are designed to administer disease-fighting
genes to provide new treatment options for large patient populations with
cancer and diabetes who currently have limited treatment options. Genprex works
with world-class institutions and collaborators to in-license and develop drug
candidates to further its pipeline of gene therapies in order to provide novel
treatment approaches. The Company’s lead product candidate, Oncoprex(TM), is
being evaluated as a treatment for non-small cell lung cancer (“NSCLC”).
Oncoprex has a multimodal mechanism of action that has been shown to interrupt
cell signaling pathways that cause replication and proliferation of cancer
cells; re-establish pathways for apoptosis, or programmed cell death, in cancer
cells; and modulate the immune response against cancer cells. Oncoprex has also
been shown to block mechanisms that create drug resistance. In January 2020,
the U.S. Food and Drug Administration granted Fast Track Designation for
Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib
(AstraZeneca’s Tagrisso(R)). For more information, please visit the company’s
website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
